



UvA-DARE (Digital Academic Repository)

Hippocampal neuropathology in suicide

Gaps in our knowledge and opportunities for a breakthrough

Zhang, L.; Lucassen, P.J.; Salta, E.; Verhaert, P.D.E.M.; Swaab, D.F.

DOI

[10.1016/j.neubiorev.2021.12.023](https://doi.org/10.1016/j.neubiorev.2021.12.023)

Publication date

2022

Document Version

Final published version

Published in

Neuroscience and Biobehavioral Reviews

License

CC BY

[Link to publication](#)

Citation for published version (APA):

Zhang, L., Lucassen, P. J., Salta, E., Verhaert, P. D. E. M., & Swaab, D. F. (2022). Hippocampal neuropathology in suicide: Gaps in our knowledge and opportunities for a breakthrough. *Neuroscience and Biobehavioral Reviews*, 132, 542-552. <https://doi.org/10.1016/j.neubiorev.2021.12.023>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



Hippocampal neuropathology in suicide: Gaps in our knowledge and opportunities for a breakthrough

Lin Zhang^a, Paul J. Lucassen^b, Evgenia Salta^c, Peter D.E.M. Verhaert^d, Dick F. Swaab^{a,*}

^a Neuropsychiatric Disorders Group, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands

^b Brain Plasticity Group, Swammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, the Netherlands

^c Neurogenesis and Neurodegeneration Group, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands

^d ProteoFormIX BV, JLABS@BE, Janssen Pharmaceutica Campus, Beerse, Belgium

ARTICLE INFO

Keywords:

Suicide
Human hippocampus
Neuropathology
Cognition
Legal euthanasia
Single-nucleus RNA sequencing
Mass spectrometry histochemistry

ABSTRACT

Suicide is a major global hazard. There is a need for increasing suicide awareness and effective and evidence-based interventions, targeting both suicidal ideation and conduct. However, anti-suicide pharmacological effects are unsatisfactory. The human hippocampus is vulnerable to neuropsychiatric damages and subsequently releases psychobiological signals. Human hippocampal studies of suicide completers have shown mechanistic changes in neurobiology, which, however, could not reflect the neuropathological ‘fingerprints’ of fatal suicide ideations and suicide attempts. In this review, we provide several leading theories of suicide, including the serotonergic system, Wnt pathway and brain-derived neurotrophic factor/tropomyosin receptor kinase B signalling, and discuss the evidence for their roles in suicide and treatment. Moreover, the cognitive dysfunctions associated with suicide risk are discussed, as well as the novel evidence on cognitive therapies that decrease suicidal ideation. We highlight the need to apply multi-omics techniques (including single-nucleus RNA sequencing and mass spectrometry histochemistry) on hippocampal samples from donors who died by suicide or legal euthanasia, to clarify the aetiology of suicide and propose novel therapeutic strategies.

1. Introduction

Suicide is a worldwide major public health and societal problem that involves over 700,000 human lives lost every year (WHO, 2021), while twenty times more people attempt suicide. The suicide rate in European countries has been gradually rising. In the Netherlands, the number of suicides is increasing by between 3 and 6 % annually. Preventive measures are lacking efficacy (Zalsman et al., 2016), and almost half of the suicide cases in the Netherlands are conducted by individuals receiving psychotropic drugs. Suicide is also the fourth leading cause of death among teenagers and adolescents (WHO, 2021). Belgium has the highest suicide rates among the European countries, where almost a quarter of the young population has had suicidal thoughts or attempted suicide in the last 12 months (Belgium, 2021). Psychiatric disorders, such as mood disorder (MD) and repeated suicide attempts, are the main risk factors for suicide completion (Beghi et al., 2021; Turecki et al., 2019). While

suicide is often considered the worst outcome or consequence of psychiatric disorders, little attention has been paid to its independent, and likely unique, molecular-genetic background (Wang et al., 2019).

The hippocampus (HC) is a subcortical brain region that is highly sensitive to stress and richly endowed with glucocorticoid receptors (GR) in humans (Wang et al., 2013). It is part of the limbic-cortical-hypothalamic circuit, which is implicated in the pathophysiology of suicide (Lutz et al., 2017; Mahar et al., 2017). Neuroimaging studies have discovered a smaller HC in suicide, along with significant histopathological changes. Hippocampal subregions were shown to be anatomically and functionally distinct, which was also reflected in suicide-specific changes. For example, fewer granular neurons and more glia with larger nuclei by age were reported in the dentate gyrus (DG), while more neurons but fewer astrocytes were found in the *Cornu Ammonis* (CA) 2/3 subareas of the HC in individuals with major depressive disorder (MDD) who died of suicide (Boldrini et al., 2019;

* Corresponding author at: University of Amsterdam, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, the Netherlands.

E-mail address: d.f.swaab@nin.knaw.nl (D.F. Swaab).

<https://doi.org/10.1016/j.neubiorev.2021.12.023>

Received 18 July 2021; Received in revised form 3 December 2021; Accepted 10 December 2021

Available online 11 December 2021

0149-7634/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Chen et al., 2020; Cobb et al., 2016, 2013), suggesting that components involved in the basic circuits of HC may perform functionally distinct roles in suicide development. In addition, antidepressants increased neural progenitor cells in the DG of subjects with MDD, which seems to be more specific to suicidal death than non-suicidal death (Boldrini et al., 2009; Lucassen et al., 2010).

While the neuropathology of suicidality was so far based upon HCs from subjects who had all completed suicide, a major problem for those studies is that it is hard to distinguish the molecular similarities and differences between suicide ideation, suicide attempts (single/repeated), and completed suicide. Strikingly, recent magnetoencephalographic studies showed that a specific type of electrophysiological connectivity and dynamics in the left HC was linked to suicidal thoughts in patients with MDD (Jiao et al., 2019; Nugent et al., 2020). While this novel finding points towards a putative neurobiological substrate and possible diagnostic marker for (the onset of) suicidality, it awaits future confirmation.

This review discusses the clinical and neuropathological manifestations in the human HC in association with suicidality. We searched the PubMed database until November 2021 using the medical subject headings search terms of hippocampus and suicide. In addition, we discuss the current antidepressants, which are prescribed with the hope of reverting the hippocampal alterations found in suicide, and their adverse effects in suicide intervention. We further discuss the unique opportunity of the HC from brain donors who died of legal euthanasia, to study differences between suicide ideations and attempts. Finally, we propose the employment of single-nucleus RNA sequencing and mass spectrometry histochemistry (MSHC) as future key spatial ‘-omics’ technologies to investigate the biomolecular fingerprints of different aspects of suicide severity. The objective is to obtain a better understanding of the cellular and molecular mechanisms that underlie suicide ideation and suicidal behaviour, and of potential novel targets for anti-suicidal therapies.

2. Suicide and hippocampal atrophy

Various structural and functional imaging studies have reported that the HC is dynamically and volumetrically disorganized in patients with psychiatric disorders and suicidality. Of note, MDD, as the condition most frequently linked to suicide, is associated with structural changes in the HC. Previous meta-analyses suggest a reduction in the hippocampal volume of subjects with MDD, which is absent in bipolar disorder (BD) (Campbell et al., 2004). Depressed patients with suicidal ideations show no volumetric alterations but do show a decreased dynamic activity in the HC compared to non-suicidal individuals with depression (Jiao et al., 2019; Lan et al., 2019). Different from suicide ideators, suicide attempters exhibit a regional asymmetry in their left HC, independent of their psychiatric disorder (Cao et al., 2015). For example, suicide attempters with MDD show evidence of higher hippocampal functional connectivity (Wagner et al., 2021; Weng et al., 2019).

MDD patients with repeated or acutely strong suicide attempts further show much smaller hippocampal volumes than patients with a first suicide attempt, non-suicidal patients, or healthy controls (Colle et al., 2015; Kang et al., 2020; Sarkinaite et al., 2021). Reversely, in adolescent and young populations, suicide attempters with MDD have larger white matter subfields than non-suicidal patients (Zhang et al., 2021b). Suicidal attempters with BD also appear to have significantly reduced grey matter volume in the HC as compared to non-suicidal BD patients (Johnston et al., 2017; Niu et al., 2019). Hippocampal volume is reduced in schizophrenia (SCZ) (Nelson et al., 1998), but suicidality-associated hippocampal atrophy does not appear in SCZ (Spoletini et al., 2011), suggesting that reduced hippocampal volume may be a promising selective neuroimaging marker to predict suicidality in MD.

3. Suicidality and cognitive impairment

Suicide is regarded to be a cognitive disorder because it strongly disturbs the mental processes involved in gaining knowledge and comprehension. The human HC is a crucial structure for such cognitive abilities and processing. Suicide-associated cognitive impairments have posed differences across ages. In psychiatrically hospitalized children, a sluggish cognitive tempo is associated with their increased suicide risk (Becker et al., 2016). These children also show decreases in episodic memory, which probably extends into adolescence and adulthood, where suicide attempts are also correlated with decreased memory performance (Huber et al., 2020). In adolescents, there is a significant association between specific cognitive characteristics and suicidal behaviours, with self-harm being among the strongest risk factors for eventual suicide death (Sinyor et al., 2020). Youths who attempt suicide are at high risk for repeated attempts and subsequently diagnosed mental health problems. They show general deficits in cognitive control towards emotional stimuli, a potential marker for adolescent suicide tendencies (Stewart et al., 2017). An increased risk for suicide completion in young males was associated with extreme cognitive abilities and poor social functioning (Weiser et al., 2017), while in young females, sleep disturbances are more likely linked to the onset of suicidal ideations (Bozzay et al., 2016).

Adults with suicide ideations can display social alienation due to perceived burdensomeness and thwarted belongingness, cognitive distortions, high reactivity to hopelessness, and aggression (Antypa et al., 2010; Fazakas-DeHoog et al., 2017; Jahn et al., 2015; Jankowski et al., 2020). In addition, susceptibility to suicidal thoughts seems to be induced via increasing anxiety sensitivity and rising cognitive concerns, robust predictors of suicide risk among patients with mental illnesses (Capron et al., 2013; Oglesby et al., 2015; Tucker et al., 2016). Compared to suicide ideators, people who have attempted suicide perform significantly worse on mental-state examinations including having a stronger self-blame, rumination, catastrophizing impulsiveness, and thus developing lethal behaviours (Abdollahpour Ranjbar et al., 2021; Gilbert et al., 2011). They also have less sense of acceptance, lower attention control, and hampered abilities of learning and memory (Abdollahpour Ranjbar et al., 2021; Alacreu-Crespo et al., 2020). In addition, relative to individuals who had either suicide ideations or undertook one single attempt, people who attempted suicide repeatedly showed worse neuropsychological performance (Delaney et al., 2012), suggesting that repeated suicidal behaviours might be related to impaired cognition. On the other hand, some studies seemed to show that the cognitive status of suicide attempters might not simply reflect a graver condition compared to the cognition of suicide ideators. For example, while cognitive inflexibility was prevalent among suicide ideators (Miranda et al., 2012; Roush et al., 2019), cognitive flexibility remained intact in suicide attempters (Brokke et al., 2020). Furthermore, regardless of their prior psychiatric disorder, suicide attempters have higher cognitive functions, such as normative planning and choice consistency (Alacreu-Crespo et al., 2020; Moniz et al., 2017). The above findings suggest that there might be distinct neurobiological mechanisms underlying suicidal ideations and suicide attempts, respectively.

In the aged population, people diagnosed with a recent mild cognitive impairment or dementia are at an increased risk of attempting suicide (Günak et al., 2021), when suicide attempters demonstrate a pattern of deficits involving poorer abstract thinking and conceptual reasoning (McGirr et al., 2012; Olsson et al., 2016). Of note, suicide-associated cognitive dysfunction, such as decision-making impairments, were also apparent in healthy first-degree relatives of suicide completers (Hoehne et al., 2015). This may be related to the observation that individuals with relatives who completed suicide are more likely to attempt suicide (Qin et al., 2002). Thus, for every age group, the profiling of molecular patterns in association with the monitoring of cognitive performance and the pertinent brain morphology in the HC will be critical in a better understanding of the pathological mechanisms

of suicide, as well as in improving the diagnosis and treatments.

Importantly, the cognitive deficits we summarized above were more prominently connected with the HC in structure and function (Brambilla et al., 2013; Chung et al., 2021; Hanseeuw et al., 2016; Khoury et al., 2019; Tang et al., 2021; Wixted et al., 2014) as compared to the other brain regions that were also reactive to (the early phase of) suicidality, such as the dorsolateral prefrontal cortex and insula (Nugent et al., 2020). In addition to the neuroimaging observations, HC-associated cognitive manifestations in clinical practice could be more sensitive in predicting an early phase of suicidality, suggesting that the HC might be a pertinent and regionally-specific target for suicide-related cognition repair and early prevention.

4. Biological mechanisms in the hippocampus that are associated with suicide

4.1. Epigenetic marks of suicide in the hippocampus

As one of the main mechanisms through which environmental and genetic factors interact with each other, epigenetic modifications in the HC are assumed to contribute to the development of suicidal behaviours (Kouter et al., 2019). Heritable phenotypic alterations, e.g. via DNA methylation and histone modification, reflect the multifactorial and polygenic state of suicide. A genome-wide methylation study on hippocampal tissue comparing suicide completers with non-psychiatric control subjects revealed a series of methylated DNA promoters that were functionally involved in learning and memory, and neuronal communication, such as synaptic transmission (Labonté et al., 2013). In addition, risk factors of suicide can alter the epigenetic status of specific genes. A specific genotype of the somatostatin receptor 4, a receptor that is predominantly found in the CA1, is involved in memory formation and related to an increased risk of suicide in individuals with alcohol dependence (Berent et al., 2017). Moreover, early life adversity is known as a relationship-associated suicidality factor, increasing the risk for various psychiatric disorders and posing a significant risk for attempting suicide. In particular, decreased levels of several human GR variants were found in the HC of suicide completers with a history of childhood abuse versus suicides without such history (Labonté et al., 2012). Also, hypermethylation of the ribosomal RNA gene promoter U13369 was consistent with reduced ribosome RNA expression in suicide subjects with a history of early childhood neglect/abuse (McGowan et al., 2008).

4.2. Gene expression and signal pathways concerning suicide

4.2.1. Serotonin receptor 2A (5-HT2AR)

The human HC has a particular role in regulating the serotonergic system. Serotonin (5-hydroxytryptamine, 5-HT) is involved in various mental processes such as cognition, memory, anxiety and mood by activating its specific receptors that are regionally distributed throughout the brain. Both depression and suicide are accompanied by modulation of distinct 5-HT receptor subtypes in the human HC. It is widely accepted that an overall downregulation of the 5-HT1A system is characteristic for depression (Yohn et al., 2017), without an influence of suicide (López et al., 1998). Where the concentrations of 5-HT and its turnover and transporter were not altered by suicidality (Anisman et al., 2008; Cheetham et al., 1989; Little et al., 1997), its main metabolite, i.e. 5-hydroxyindoleacetic acid, was increased in the HC of depressed patients who died by suicide (Cheetham et al., 1989; Owen et al., 1986).

Also, 5-HT2AR is abundant in the HC of patients who completed suicide. Previous studies have associated polymorphisms of the 5-HT2AR gene with a biological susceptibility to suicide attempts (Vaquero-Lorenzo et al., 2008). The expression of 5-HT2AR is also higher in the HC of suicide victims, while its binding potential, combining receptor density and the affinity of serotonin, was not altered (Pandey et al., 2002; Roth et al., 1990; Soloff et al., 2007). Others

showed that the binding sites of 5-HT2 receptors in the HC were diminished in antidepressant-free individuals who died by suicide compared to control subjects (Cheetham et al., 1988). This is likely due to a reduction of 5-HT2A binding sites accompanied by higher serotonin affinity (Rosel et al., 2004, 1998). Moreover, while the presynaptic uptake of serotonin was decreased in suicide cases as compared to the controls, the 5-HT2A postsynaptic receptor was hypersensitive in line with a high affinity of this receptor subtype (Rosel et al., 2000, 1997).

Taken together, the above evidence indicates that suicide may possibly trigger a synaptopathy in hippocampal cells. Functionally, a microarray analysis has revealed alterations of synaptic neurotransmission in the hippocampus of subjects who died by suicide (Sequeira et al., 2009). In synaptic structures, decreases of synapsin/synaptophysin ratio and postsynaptic density protein 95 have been found in the hippocampus of suicide victims (Sowa-Kućma et al., 2013; Vawter et al., 2002), suggesting that suicide may have affected synaptic components and plasticity. One of the major results is 5-HT2AR-mediated postsynaptic hyper-excitability during serotonin transmission. Downstream of the 5-HT receptors, a decreased activity of protein kinase B (PKB or Akt) has been reported in the HC of suicide victims with depression compared to non-psychiatric control subjects (Fig. 1) (Dwivedi et al., 2010). In addition, 5-HT receptor ligands and purine nucleotides were shown to have molecular similarities in terms of their receptor regulatory properties, such as crosstalk between the 5-HT2A receptor and P2Y purinoceptor 12 in 5-HT storage during platelet aggregation, and in suicide as well (Vaquero-Lorenzo et al., 2008; Zhang et al., 2020a, b; Zhang et al., 2021a). Other depression-associated receptors, such as 5-HT1A, 5-HT1C, 5-HT2C, and 5-HT4 did not display alterations in the HC of suicide completers (López et al., 1998; Lowther et al., 1997; Pandey et al., 2006; Rosel et al., 2004; Roth et al., 1990). Of note, the above findings were derived from suicide victims who had suffered from depression as well and were analyzed by comparing them to non-psychiatric controls, indicating that the possible influence of the psychiatric disorders could have been overlooked (Zhao et al., 2019).

4.2.2. Brain-derived neurotrophic factor system

The brain-derived neurotrophic factor (BDNF) is highly expressed in the human HC and it is a critical mediator of physical activities. Among others, BDNF supports neuronal survival and promotes the growth and differentiation of immature neurons and synapses (Duman et al., 2021; Marlatt et al., 2012; Notaras and van den Buuse, 2020). As a well-known genetic locus of risk for mental disorders, BDNF is associated with stress and stress-related disorders (Castrén and Rantamäki, 2010; Molendijk et al., 2014; Shirayama et al., 2002). The presence of BDNF Val66Met polymorphism is even proposed as an independent predictor of high lethality in suicide attempts of depressed patients (Schenkel et al., 2010).

In conditions of prolonged stress, the influx of increased glucocorticoids into the HC activates the mitogen-activated protein kinase (MAPK) pathway via phosphorylation of its receptor tropomyosin-related kinases B (TrkB), and thereby enhances negative memory formation (Notaras and van den Buuse, 2020). Dysfunctional BDNF in depression and suicide probably share common pathways and may procure similar hippocampal malfunctions (Fig. 1). Previous studies have reported an overall breakdown of BDNF as well as the downstream-regulated molecules in the HC of depressed patients (Molendijk et al., 2014). At the extracellular and membrane levels, reduced BDNF results in lower levels of the transmembrane receptor TrkB, its activation resulting in decreased intracellular signalling among the phosphatidylinositol-3-kinase/Akt and MAPK-ERK kinase/MAPK pathways (Banerjee et al., 2013; Dwivedi et al., 2001, 2006; Dwivedi et al., 2003b, 2008; Dwivedi et al., 2009a,b, 2010; Karege et al., 2005; Pandey et al., 2008). Consequently, intra-nuclear expression and functional characteristics of cyclic adenosine monophosphate response element-binding protein, a transcription factor that triggers expression of various genes involved in neurogenesis and mood regulation, has




Fig. 1. Schematic illustration of altered molecules in 5-HT, BDNF and Wnt pathways in the homogenate HC of depressed suicide. Molecules in red show down-regulation. Molecules in blue show, so far to our knowledge, no alterations have been reported. The molecule in yellow reveals up-regulation in signal cascades. By summing up this review, we considered that an excessive release of intracellular neuronal inhibitor dopamine may trigger a hyperpolarization of the postsynaptic membrane and thus activate postsynaptic 5-HT_{2A}R, which produces a long-lasting depression to the downstream molecules. The figure is based on the literature of the present review and partly on modified figures by Voleti and Duman (Voleti and Duman, 2012). Abbreviations: Akt, protein kinase B; APC, adenomatosis polyposis coli; β -Cat, β -catenin; BDNF, brain-derived neurotrophic factor; CREB, cAMP response element-binding; Dvl, Disheveled; ERK; extracellular signal-regulated kinase; 5-HT, serotonin; 5-HT_{2A}R; serotonin receptor 2A; Fz, frizzled; GSK-3 β , glycogen synthase kinase β ; HC, hippocampus; LEF, lymphoid enhancer-binding factor; MAPK, mitogen-activated protein kinase; MEK, MAPK-ERK kinase; NFAT, nuclear factor of activated T-cells; p, phosphorylation; PI3K, phosphatidylinositol-3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKC, protein kinase C; PP2A, protein phosphatase; TCF, T-cell factor; TrkB, tyrosine kinase receptor B. (Fig. 1 is created with BioRender.com. Agreement number: QO22Q30PVD).

been found decreased in the HC (Dwivedi et al., 2003a). Decreased histone acetylation and increased levels of factors related to de-acetylation and methylation processes also have been reported to lower BDNF, which may trigger subsequent alterations (Misztak et al., 2020).

Of note, the above-mentioned studies all were performed on hippocampal tissue from patients who died by suicide. The data were compared to healthy controls, and, thus, the contribution of the underlying psychiatric disorders themselves was not considered as a putative confounder (Zhao et al., 2019).

4.2.3. Wnt signalling

A role for the Wnt pathway in suicidal behaviours has been reported in several studies on the human postmortem HC. Generally, Wnt signalling is a pivotal regulator of cell proliferation, specification and migration. Molecules activated by the BDNF pathway are also involved in the modulation of Wnt signalling (Fig. 1). Three different Wnt signalling pathways have been described: a canonical pathway and two non-canonical ones. In the canonical pathway, the activity of Akt is influenced by serotonergic and BDNF systems. Both Wnt and BDNF signalling are coupled to activation of intracellular signalling cascades that involve phosphorylation of glycogen synthase kinase β (GSK-3 β) (Voleti and Duman, 2012). This key downstream enzyme controls the translocation of β -catenin to the nucleus and activates the transcription of Wnt target genes. In the HC of suicide victims, pGSK-3 β -ser⁹, the phosphorylated isoform of Ser9 that exhibits a reduced activity, and β -catenin, both showed decreased expression relative to the controls (Pandey et al., 2009). This indicates aberrations in the downstream cascades of the Wnt signalling pathway, whereas GSK-3 β itself does not show marked changes in expression (Ren et al., 2013).

On the other hand, reduced activity of protein kinase C (PKC) levels has been reported in the HC of suicide cases compared to non-psychiatric control subjects. PKC is a midstream molecule involved in

the non-canonical Wnt pathway that downregulates the MAPK/ERK signals and subsequent cascades (Dwivedi et al., 2003a; Voleti and Duman, 2012). This is in accordance with a decreased phosphorylation of its substrate in the HC (Pandey et al., 2003). It also supports the synergistic effect between BDNF and non-canonical Wnt pathways (Fig. 1). Taken together, this evidence emphasizes that data obtained after mixing suicide and depression in the same comparison may be interpreted with more prudence.

4.2.4. Glucocorticoid receptor

Long-term, stress-induced glucocorticoid elevation impairs hippocampal neuroplasticity and neurogenesis, and is involved in functional (feedback) abnormalities of the hypothalamus-pituitary-adrenal (HPA) axis that can, to some extent, be normalized by antidepressant drugs (Anacker et al., 2018; Brummelte and Galea, 2010; Lucassen et al., 2013, 2015; Snyder et al., 2011; Surget et al., 2011). A recent retrospective analysis has shown that oral glucocorticoids were associated with a robust increased risk of suicide in a dose-dependent manner (Laugesen et al., 2021). Although previous findings did not reveal obvious alterations in the cellular integrity or total transcripts of the human HC in relation to depression or glucocorticoid treatment, we later observed an increased expression of the GR in hippocampal CA1 of MDD patients, which interestingly, appeared higher in females than in males (Klok et al., 2011; Müller et al., 2001; Wang et al., 2012). In addition, glucocorticoid stress hormones that act on the GR have been proven to interact with the BDNF Val66Met polymorphism to determine hippocampus-gated fear and spatial memory (Notaras et al., 2016). In contrast, current studies did not reveal changes in the HC in molecules involved in the HPA circuitry in relation to suicide, including corticotropin-releasing hormone, its receptors and binding protein, or GR (isoforms) (Medina et al., 2013; Pandey et al., 2019, 2013). Other studies hypothesize that early life adversity, but not suicide, was the primary cause of subfield volume and plasticity changes, and

dyregulation of the GR gene in the HC (Alt et al., 2010; Boldrini et al., 2019; Labonté et al., 2012; McGowan et al., 2009; Teicher et al., 2012; Youssef et al., 2019). However, these hippocampal measurements were performed in bulk hippocampal preparations, which might preclude the profiling of the unique effects of glucocorticoids on specific cell populations in the hippocampus.

4.2.5. Androgen receptor

Androgens are steroid hormones involved in adult hippocampal neurogenesis and mood regulation by selectively binding to androgen receptor (AR) subtypes (Hamson et al., 2013; Zhang et al., 2010). Circulating levels of testosterone have been positively associated with suicidal behaviours in patients with depression (Sher et al., 2012). Postmortem studies have shown that the HC of suicide subjects has a stronger binding potential of AR- α 2, as evidenced by increased receptor density and binding affinity relative to non-suicidal depressed patients and non-psychiatric controls (González et al., 1994; Meana et al., 1992). In contrast, AR- β expression in the HC did not exhibit alterations between suicide and control (Gurguis et al., 1999), yet the asymmetric expression of AR- β 2 between hemispheres in the control group was absent in suicidal cases (Joyce et al., 1992). So far, the mechanisms of androgen involvement in suicidality remain elusive.

5. Anti-suicidal interventions associated with cognitive improvement

5.1. Cognitive-behavioural therapy

Cognitive-behavioural therapy (CBT) has been widely applied, and its efficacy towards suicide prevention has been proven across ages and following various adverse life triggers, including self-injury, post-traumatic stress disorder, sexual assault, and cognitive degeneration. Early intervention with CBT, via education and support to access community treatment, is crucial for decreasing suicide thoughts and self-injury, especially in young people at risk of suicide, who are, however, frequently not seeking treatment (Asarnow et al., 2017; Hetrick et al., 2017; Weinstein et al., 2018).

In adults, CBT is effective in preventing suicide attempts for patients with depression and/or a history of recent suicide attempts (Brown et al., 2005). Brief CBT and mindfulness-based cognitive therapy have been shown to reduce suicide risk by regulating cognitive reactivity, including measures of hopelessness and suicide beliefs (Chesin et al., 2016; Roberge et al., 2019). Given that mild cognitive impairment and dementia have been implicated in part of the aged suicide attempters, supportive services and cognitive reappraisal intervention may prevent the elderly from being hospitalized for suicidality (Günak et al., 2021; Lin et al., 2019). Of note, cognitive and working memory deficits may result directly from polysubstance use in the elderly and contribute to current serious suicidal ideation and attempts (Pompili et al., 2007). However, CBT was not beneficial in reducing suicidality when this occurred as a comorbidity of substance abuse (Morley et al., 2014), indicating that addiction-suicide interactions can have an independent impact on the pathogenesis and therapeutic barrier of suicide. Thus, cognitive improvement, possibly via CBT, plays an important role and marks the favourable prognosis of anti-suicidal therapies.

As we summarized in Fig. 1, a decrease of neurotrophic intracellular molecules has been associated with alterations in several signalling pathways. A correction of BDNF levels may therefore improve the deficiency of downstream cytoplasmic molecules and, eventually, reverse intranuclear transcriptional regulation. A clinical trial has shown that plasma levels of BDNF can serve as an indicator of treatment response associated with the recovery of suicide ideations (Grunebaum et al., 2017). In addition, therapeutic effects of CBT are dependent on the BDNF Val66Met polymorphism (Peters et al., 2020). Therefore, we hypothesize that the serum increase of BDNF could be a long-term effect of CBT therapies (Kobayashi et al., 2005), and the increase itself may be

antisuicidal.

5.2. Serotonin receptor 2A ligands

The observations discussed above indicate that increased post-synaptic 5-HT_{2A}R level in the human HC may be involved in the pathogenesis of suicide. One may thus assume that either agonists or antagonists of the 5-HT_{2A}R could provide an anti-suicidal effect. So far, however, most 5-HT_{2A}R agonists or antagonists did not yield an improvement of the onset or progression of suicidality. However, some prescribed formulations have even been found to be associated with elevated suicide risk, possibly due to initial responses and adaptations in the 5-HT system. Among the agonists, for example, clinical application of 25I-NBOME that maps the cerebral localization of 5-HT_{2A}R was found to be associated with more suicide attempts (Nichols and Grob, 2018; Suzuki et al., 2014). In addition, partial agonists of 5-HT_{2A}R caused more lethal and negative psychiatric effects. Among human immunodeficiency virus-infected adults treated with efavirenz, an antiretroviral compound that is also a 5-HT_{2A}R agonist, an increased risk of suicidal ideation was related to its plasma level (Mollan et al., 2014, 2017; Ophinni et al., 2020). Furthermore, exposure to mefloquine, an antimalarial drug, has also been associated with violent acts and suicidal behaviours (Nevin, 2012; Ritchie et al., 2013). Moreover, selective 5-HT_{2A}R antagonists that inhibit serotonin reuptake, such as trazodone and mirtazapine, were both related to higher rates of suicide ideation, attempts, and self-harm behaviours (Coupland et al., 2015; Lavigne et al., 2019; Tubbs et al., 2021). The atypical antipsychotic olanzapine, whether or not it was associated with higher suicide-related events or the prevention of suicide, was found to be dependent on the underlying psychiatric illnesses of patients (Delapaz et al., 2021; Reutfors et al., 2013). A 5-HT_{2A}R antagonist is more likely to play a positive role in suicide intervention when it also blocks the dopaminergic system, as it is in the case of risperidone or olanzapine (Reutfors et al., 2013). Similarly, cyproheptadine is a preventive measure to reduce the adverse effects triggered by efavirenz-included antiretroviral therapy (Dabaghzadeh et al., 2013). It seems thus that simply activating or blocking the activity of the 5-HT_{2A}R does not relieve suicidality, but synergism with other neurotransmitters and neuromodulators may be effective. Evidently, more studies are needed to illustrate the mechanistic involvement of 5-HT_{2A}R in suicide.

5.3. Ketamine

In recent years, ketamine has become a novel drug in suicide interventions. Many studies have confirmed that ketamine can rapidly alleviate suicide thoughts regardless of the administered frequency (single/repeated) or mode (intravenous/intranasal/oral) (Beaudequin et al., 2020; Domany and McCullumsmith, 2021; Grunebaum et al., 2017, 2018). Ketamine has been broadly prescribed to patients with MD, SCZ, or non-psychiatric individuals with recent suicide ideations (Domany et al., 2020; Fan et al., 2017; Grunebaum et al., 2017, 2018). The benefit of the significant reduction in suicide ideations induced by ketamine is enhanced by its being safe and well-tolerated. Its anti-suicidal effect is partly independent of the underlying psychiatric disorders or mood dysregulation (Ballard et al., 2014; Kang et al., 2021).

Interestingly, improvements in BDNF levels and memory, especially working memory, emerge as promising markers for the anti-suicide efficacy of ketamine treatment (Chen et al., 2021; Grunebaum et al., 2017). In clinical practice, short-term ketamine administration has pro-cognitive effects, e.g. in improving executive function and emotional processing (Lee et al., 2016). To date, both animal and human studies profiling neurobiological phenotypes and mechanisms have demonstrated that short-term ketamine intake is associated with reduced neuroinflammation, normalized glutamatergic hyperexcitability and synaptic plasticity (including BDNF, GSK-3, and TrkB receptor), modified dopamine synthesis and parvalbumin expression, and

activation of the opioid system in the HC (Al Jurdi et al., 2015; Kokkinou et al., 2020; Luo et al., 2020; Nowak et al., 2019; Williams et al., 2019; Zanos and Gould, 2018). In addition, acute ketamine administration has been found to induce dopamine release in the rodent brain, further supporting its antidepressant potential (Kokkinou et al., 2018). This observation also suggests that reducing the intracellular dopamine content may be a putative anti-suicidal target. Moreover, MDD patients who bear a BDNF Val66Met polymorphism showed a weakened antidepressant response of ketamine as compared to non-Met carriers (Laje et al., 2012). Interestingly, this allele also impairs ketamine-stimulated synaptogenesis in mice (Liu et al., 2012).

However, our knowledge of safety data on long-term ketamine use, such as irresponsive cases, tolerance, possible adverse effects associated with discontinuation, and potential abuse is worth mentioning. For example, compared to individuals with acute and moderate suicidality, those who had a chronic and strong suicide ideation responded with less anti-suicidal effects to ketamine (Ballard et al., 2018; Zhan et al., 2019). In addition, suicide attempts during maintenance ketamine treatment were also reported (Cusin et al., 2020). Strikingly, it has been shown that long-term ketamine use could produce cognitive deficits partly because it restrains synaptic signalling (Luo et al., 2020). Therefore, understanding the specific mechanistic alterations in subjects who have suicide ideations or attempted suicide, but did not die by suicide, can help in the future to avoid or modify risk factors and adverse actions that occur in suicide interference. The study of hippocampal brain samples of such individuals may be particularly useful in that regard and in further developing novel pertinent therapeutic strategies.

6. The future of suicide research: a promise and a focus on novel technologies

6.1. Opportunities using the hippocampus of legal euthanasia donors

Suicide is a progressive disorder and we presume that suicide thoughts, suicide attempts and their severity, and suicide completion correlate with increasing neuropathological alterations in the human brain. Aberrant signal pathways summarized above have indicated the presence of a molecular diversity implicated in the HC in relation to suicidality. However, the neurobiological changes exhibited by subjects who completed suicide are generally considered as strong molecular features of the underlying mental illnesses. Our previous studies were devoted to unravelling the neuropathology of psychiatric diseases and suicide as separate entities that have revealed different molecular changes in relation to MD and suicide (Zhang et al., 2020a, b; Zhang et al., 2021a; Zhao et al., 2019).

In addition to completed suicide, we recently introduced, for the first time, brain samples from individuals who died of legal euthanasia (people who had strong death ideation or even attempted suicide but were eventually euthanized) to explore the stages of suicidality in different ways (unpublished results). First, with euthanasia samples, we could classify the pathogenesis of suicide thoughts and suicidal behaviours as single or repeated attempts, which may ultimately be essential for personalized medication applications according to severity and complications. Second, individuals who died of legal euthanasia may have comorbid psychiatric illnesses or be non-psychiatric ‘controls’, e.g. cancer patients. This way, we could distinguish biomarkers between subjects with psychiatric disorders, who died of natural causes, versus subjects who died of legal euthanasia. The same holds for the control cases, which will enable us to analyze whether differential gene expression may be due to suicide tendency per se, or to the underlying psychiatric disorders. Third, by comparing subjects who died of legal euthanasia but did not attempt suicide throughout their lifespan, and subjects who died of natural causes but had suicidal ideations during their lifetime, we can profile vulnerability or resilience gene signatures that explain the potential conversion from suicide thoughts to actual suicides. Fourth, by comparing the differential gene expression patterns

derived from subjects with psychiatric illnesses, versus controls in the euthanasia group, and differential patterns derived from the same subset analysis within natural deaths, we hope to identify the target genes of high suicidality among patients with psychiatric disorders.

6.2. Application of single-nucleus RNA sequencing

Evidently, mapping the cellular and molecular complexity of the events that underlie the conversion from suicide ideation to suicide completion will be key to identifying novel and putatively druggable regulators and pathways. Only a handful of studies assaying the human ‘suicide’ brain in an unbiased, genome-wide manner, and in relation to MDs, or rather independently of them, have been published to date (Glavan et al., 2021; Jabbi et al., 2020; Pantazatos et al., 2017; Punzi et al., 2019; Zhou et al., 2018). Strikingly, a common theme emerging from all these reports is the involvement of immune and inflammatory responses in the transcriptomic signatures related to suicide. These responses were associated not only with neuronal cells and pathways but also with astrocytes and microglia, highlighting the significance of multi-cellular crosstalk in shaping behaviours linked to suicide. Moreover, these findings suggest that decoding hub regulators driving suicide-associated behaviours cannot be achieved by bulk approaches and necessitates single-cell resolution. Even though no such evidence currently exists with respect to suicide subjects, single-nucleus RNA sequencing has been successfully applied to a wide range of human brain disorders, ranging from neurodegenerative to neuropsychiatric illnesses (Al-Dalahmah et al., 2020; Davila-Velderrain et al., 2021; Del-Aguila et al., 2019; Mathys et al., 2019; Nagy et al., 2020). While some concerns have been reported with respect to how representative the nuclear transcriptome is for the cellular transcriptome in the human post-mortem brain (Thrupp et al., 2020), studies directly comparing gene expression data from single nuclei versus single whole cells have demonstrated a high degree of concordance (Bakken et al., 2018; Lake et al., 2017; Olah et al., 2020), while disease-specific cellular states in the human brain also have been reported (Davila-Velderrain et al., 2021; Leng et al., 2021; Olah et al., 2020). Taken together, these observations may pave the way for the application of single-nucleus omics technologies to profile the cellular and molecular signatures of suicidal behaviours, and thereby identify novel targets for therapeutic intervention.

6.3. Application of mass spectrometry histochemistry

The above indicates that genes and proteins involved in specific neuronal signalling are strongly linked to suicidal tendencies. In addition, localization of molecular alterations in the brain is crucial for the interpretation of their functional consequences.

Besides the conventional ‘-omics’ technologies, we, therefore, envision a promising role in future HC studies for analytical methods, which allow the imaging of signalling biomolecules directly on histological sections. In this context, a reactive matrix-assisted laser desorption and ionization mass spectrometry imaging (MSI) method for visualizing neurotransmitters has been shown to work on cryosections (Shariatgorji et al., 2019). Moreover, recently technology has been developed based on high-resolution MSI for the localization of neuropeptides in historic collections of well-documented formaldehyde-fixed and paraffin-embedded (FFPE) tissue samples (Paine et al., 2018). Such FFPE tissues are abundantly stored in biobanks all over the globe, including the Netherlands Brain Bank (NBB). This FFPE method for localizing neuropeptides was designated MSHC. Unlike immunohistochemistry which requires specific antibodies for biomolecule detection/localization, MSHC allows the study of multiple molecules simultaneously, combining detained localization with a very high molecular specificity. Indeed, methodological aspects like the capacity to detect low expressed proteins and genes deserve attention. Techniques like MSHC together with new developments in spatial transcriptomics, RNAscope and

high-plex RNA imaging (Longo et al., 2021; Strack, 2021) allow for complete molecular structure characterization of tissue, combining high accuracy mass measurements with tandem mass spectrometry primary structure confirmation, and as such includes all the features necessary to evolve into a powerful non-targeted biomolecular discovery tool.

7. Conclusions

We have here synthesized the existing knowledge regarding the functional association of the hippocampal formation with suicide. Two major concerns merge from this review. First, the psychopathological basis of psychiatric disorders and suicide should be distinguished and studied separately. Neglecting this may very well be the reason for the so far less satisfactory effects of antidepressant or antipsychotic treatment for suicide prevention. Second, unravelling the neurobiological alterations in carefully stratified subject cohorts that fall under different categories of suicide classifications is key to ultimately enable the development of novel individual suicide treatment and prevention strategies. Considering the heterogeneity of the suicide alterations and their regional specificity in the human brain, we presented an overview of the current state of knowledge regarding pathological alterations, focusing on the HC since hippocampal atrophy and specific cognitive dysfunction are two major parameters implicated in suicidality. We have, therefore, initiated a comparative study of donors from the NBB (a scientific infrastructure that is capable to support a comprehensive analysis of the different stages of suicidality and selecting the right samples) who died of legal euthanasia, and those who completed suicide, in an attempt to detect in the human HC the neuropathological grading from the onset of suicide ideations, over single suicide attempts, to recurrent suicidal behaviours. These and other similar future studies employing multi-omics techniques on tissue samples from donors with different stages of suicidality will hopefully provide novel mechanistic insights into the pathogenesis of suicide across different stages.

Data availability

No data was used for the research described in the article.
Data will be made available on request.
The data that has been used is confidential.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgement

This review was supported by the ‘Stichting Vrienden van het Herseninstituut’.

References

- Abdollahpour Ranjbar, H., Parhoon, H., Mohammadkhani, S., Munawar, K., Moradi, A., Jobson, L., 2021. Investigating cognitive control and cognitive emotion regulation in Iranian depressed women with suicidal ideation or suicide attempts. *Suicide and Life-Threatening Behavior*.
- Al Jurdi, R.K., Swann, A., Mathew, S.J., 2015. Psychopharmacological agents and suicide risk reduction: ketamine and other approaches. *Curr. Psychiatry Rep.* 17, 1–10.
- Alacreu-Crespo, A., Guillaume, S., Sénèque, M., Olié, E., Courtet, P., 2020. Cognitive modelling to assess decision-making impairments in patients with current depression and with/without suicide history. *Eur. Neuropsychopharmacol.* 36, 50–59.
- Al-Dalahmah, O., Sosunov, A.A., Shaik, A., Ofori, K., Liu, Y., Vonsattel, J.P., Adorjan, I., Menon, V., Goldman, J.E., 2020. Single-nucleus RNA-seq identifies Huntington disease astrocyte states. *Acta Neuropathol. Commun.* 8, 1–21.
- Alt, S.R., Turner, J.D., Klok, M.D., Meijer, O.C., Lakke, E.A., DeRijk, R.H., Muller, C.P., 2010. Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. *Psychoneuroendocrinology* 35, 544–556.
- Anacker, C., Luna, V.M., Stevens, G.S., Millette, A., Shores, R., Jimenez, J.C., Chen, B., Hen, R., 2018. Hippocampal neurogenesis confers stress resilience by inhibiting the ventral dentate gyrus. *Nature* 559, 98–102.
- Anisman, H., Du, L., Palkovits, M., Faludi, G., Kovacs, G.G., Szontagh-Kishazi, P., Merali, Z., Poulter, M.O., 2008. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. *J. Psychiatry Neurosci.* JPN 33, 131.
- Antypa, N., Van der Does, A.W., Penninx, B.W., 2010. Cognitive reactivity: investigation of a potentially treatable marker of suicide risk in depression. *J. Affect. Disord.* 122, 46–52.
- Asarnow, J.R., Hughes, J.L., Babeva, K.N., Sugar, C.A., 2017. Cognitive-behavioral family treatment for suicide attempt prevention: a randomized controlled trial. *J. Am. Acad. Child Adolesc. Psychiatry* 56, 506–514.
- Bakken, T.E., Hodge, R.D., Miller, J.A., Yao, Z., Nguyen, T.N., Aevermann, B., Barkan, E., Bertagnoli, D., Casper, T., Dee, N., 2018. Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. *PLoS One* 13, e0209648.
- Ballard, E.D., Ionescu, D.F., Voort, J.L.V., Niciu, M.J., Richards, E.M., Luckenbaugh, D.A., Brutsché, N.E., Ameli, R., Furey, M.L., Zarate Jr, C.A., 2014. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. *J. Psychiatr. Res.* 58, 161–166.
- Ballard, E.D., Yarrington, J.S., Farmer, C.A., Richards, E., Machado-Vieira, R., Kadriu, B., Niciu, M.J., Yuan, P., Park, L., Zarate Jr, C.A., 2018. Characterizing the course of suicidal ideation response to ketamine. *J. Affect. Disord.* 241, 86–93.
- Banerjee, R., Ghosh, A.K., Ghosh, B., Bhattacharyya, S., Mondal, A.C., 2013. Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: an analysis in human postmortem brain. *Clin. Med. Insights Pathol.* 6, S12530. CPath.
- Beaudequin, D., Can, A.T., Dutton, M., Jones, M., Gallay, C., Schwenn, P., Yang, C., Forsyth, G., Simcock, G., Hermens, D.F., 2020. Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support. *BMC Psychiatry* 20, 1–15.
- Becker, S.P., Withrow, A.R., Stoppelbein, L., Luebbe, A.M., Fite, P.J., Greening, L., 2016. Sluggish cognitive tempo is associated with suicide risk in psychiatrically hospitalized children. *J. Child Psychol. Psychiatry* 57, 1390–1399.
- Beghi, M., Butera, E., Cerri, C.G., Cornaggia, C.M., Febbo, F., Mollica, A., Berardino, G., Piscitelli, D., Resta, E., Logroscino, G., 2021. Suicidal behaviour in older age: a systematic review of risk factors associated to suicide attempts and completed suicides. *Neurosci. Biobehav. Rev.*
- Belgium, Fah., 2021. Suicidal Behaviour.
- Berent, D., Emilien, G., Podgórski, M., Kusidel, E., Kulczycka-Wojdala, D., Szymańska, B., Macander, M., Pawłowska, Z., 2017. SSTR4, childhood adversity, self-efficacy and suicide risk in alcoholics. *Transl. Neurosci.* 8, 76–86.
- Boldrini, M., Underwood, M.D., Hen, R., Rosoklija, G.B., Dwork, A.J., Mann, J.J., Arango, V., 2009. Antidepressants increase neural progenitor cells in the human hippocampus. *Neuropsychopharmacology* 34, 2376–2389.
- Boldrini, M., Galfalvy, H., Dwork, A.J., Rosoklija, G.B., Trencsevska-Ivanovska, I., Pavlovski, G., Hen, R., Arango, V., Mann, J.J., 2019. Resilience is associated with larger dentate gyrus, while suicide decedents with major depressive disorder have fewer granule neurons. *Biol. Psychiatry* 85, 850–862.
- Bozzay, M.L., Karver, M.S., Verona, E., 2016. Linking insomnia and suicide ideation in college females: the role of socio-cognitive variables and depressive symptoms in suicide risk. *J. Affect. Disord.* 199, 106–113.
- Brambilla, P., Perlini, C., Rajagopalan, P., Saharan, P., Rambaldelli, G., Bellani, M., Dusi, N., Cerini, R., Mucelli, R.P., Tansella, M., 2013. Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study. *Br. J. Psychiatry* 202, 50–55.
- Brokke, S.S., Landrø, N.I., Haaland, V.O., 2020. Cognitive control in suicide ideators and suicide attempters. *Front. Psychol.* 11.
- Brown, G.K., Ten Have, T., Henriques, G.R., Xie, S.X., Hollander, J.E., Beck, A.T., 2005. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. *Jama* 294, 563–570.
- Brummelte, S., Galea, L.A., 2010. Chronic high corticosterone reduces neurogenesis in the dentate gyrus of adult male and female rats. *Neuroscience* 168, 680–690.
- Campbell, S., Marriott, M., Nahmias, C., MacQueen, G.M., 2004. Lower hippocampal volume in patients suffering from depression: a meta-analysis. *Am. J. Psychiatry* 161, 598–607.
- Cao, J., Chen, J.-m., Kuang, L., Ai, M., Fang, W.-d., Gan, Y., Wang, W., Chen, X.-r., Xu, X.-m., Wang, H.-g., 2015. Abnormal regional homogeneity in young adult suicide attempters with no diagnosable psychiatric disorder: a resting state functional magnetic imaging study. *Psychiatry Res. Neuroimaging* 231, 95–102.
- Capron, D.W., Norr, A.M., Macatee, R.J., Schmidt, N.B., 2013. Distress tolerance and anxiety sensitivity cognitive concerns: testing the incremental contributions of affect dysregulation constructs on suicidal ideation and suicide attempt. *Behav. Ther.* 44, 349–358.
- Castrén, E., Rantamäki, T., 2010. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. *Dev. Neurobiol.* 70, 289–297.
- Cheetham, S.C., Crompton, M.R., Katona, C.L., Horton, R.W., 1988. Brain 5-HT₂ receptor binding sites in depressed suicide victims. *Brain Res.* 443, 272–280.
- Cheetham, S.C., Crompton, M.R., Czudek, C., Horton, R.W., Katona, C.L., Reynolds, G.P., 1989. Serotonin concentrations and turnover in brains of depressed suicides. *Brain Res.* 502, 332–340.
- Chen, F., Bertelsen, A.B., Holm, I.E., Nyengaard, J.R., Rosenberg, R., Dorph-Petersen, K.-A., 2020. Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects. *Brain Res.* 1727, 146546.
- Chen, X., Wang, M., Hu, Y., Zhan, Y., Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhong, X., Li, H., 2021. Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. *Eur. Arch. Psychiatry Clin. Neurosci.* 271, 431–438.

- Chesin, M.S., Benjamin-Phillips, C.A., Keilp, J., Fertuck, E.A., Brodsky, B.S., Stanley, B., 2016. Improvements in executive attention, rumination, cognitive reactivity, and mindfulness among high-suicide risk patients participating in adjunct mindfulness-based cognitive therapy: preliminary findings. *J. Altern. Complement. Med.* 22, 642–649.
- Chung, A., Jou, C., Grau-Perales, A., Levy, E.R., Dvorak, D., Hussain, N., Fenton, A.A., 2021. Cognitive control persistently enhances hippocampal information processing. *Nature* 1–5.
- Cobb, J.A., Simpson, J., Mahajan, G.J., Overholser, J.C., Jurjus, G.J., Dieter, L., Herbst, N., May, W., Rajkowska, G., Stockmeier, C.A., 2013. Hippocampal volume and total cell numbers in major depressive disorder. *J. Psychiatr. Res.* 47, 299–306.
- Cobb, J.A., O'Neill, K., Milner, J., Mahajan, G.J., Lawrence, T.J., May, W.L., Miguel-Hidalgo, J., Rajkowska, G., Stockmeier, C.A., 2016. Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. *Neuroscience* 316, 209–220.
- Colle, R., Chupin, M., Cury, C., Vandendriessche, C., Gressier, F., Hardy, P., Falissard, B., Colliot, O., Ducreux, D., Corruble, E., 2015. Depressed suicide attempters have smaller hippocampus than depressed patients without suicide attempts. *J. Psychiatr. Res.* 61, 13–18.
- Coupland, C., Hill, T., Morriss, R., Arthur, A., Moore, M., Hippisley-Cox, J., 2015. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. *BMJ (Clin. Res. Ed.)* 350.
- Cusin, C., Sakurai, H., Bentley, K., Pedrelli, P., Foster, S., Fava, M., Mischoulon, D., 2020. All suicidal ideation is not created equal: two cases of suicide attempts during maintenance ketamine treatment. *Am. J. Psychiatry* 177, 173–174.
- Dabaghzadeh, F., Ghaeli, P., Khalil, H., Alimadadi, A., Jafari, S., Akhondzadeh, S., Khazaeipour, Z., 2013. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. *AIDS Patient Care STDs* 27, 146–154.
- Davila-Velderrain, J., Mathys, H., Mohammadi, S., Ruzicka, W.B., Jiang, X., Ng, A., Bennett, D.A., Tsai, L.-H., Kellis, M., 2021. Single-cell anatomical analysis of human hippocampus and entorhinal cortex uncovers early-stage molecular pathology in Alzheimer's disease. *bioRxiv*.
- Del-Aguila, J.L., Li, Z., Dube, U., Mihindukulasuriya, K.A., Budde, J.P., Fernandez, M.V., Ibanez, L., Bradley, J., Wang, F., Bergmann, K., 2019. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimers Res. Ther.* 11, 1–16.
- Delaney, C., McGrane, J., Cummings, E., Morris, D., Tropea, D., Gill, M., Corvin, A., Donohoe, G., 2012. Preserved cognitive function is associated with suicidal ideation and single suicide attempts in schizophrenia. *Schizophr. Res.* 140, 232–236.
- Delapaz, N.R., Hor, W.K., Gilbert, M., La, A.D., Liang, F., Fan, P., Qi, X., Guo, X., Ying, J., Sakolsky, D., 2021. An emulation of randomized trials of administering antipsychotics in PTSD patients for outcomes of suicide-related events. *J. Pers. Med.* 11, 178.
- Domany, Y., McCullumsmith, C.B., 2021. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. *Archives of Suicide Research*, pp. 1–16.
- Domany, Y., Shelton, R.C., McCullumsmith, C.B., 2020. Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. *Depress. Anxiety* 37, 224–233.
- Duman, R.S., Deyama, S., Fogaça, M.V., 2021. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. *Eur. J. Neurosci.* 53, 126–139.
- Dwivedi, Y., Rizavi, H., Roberts, R., Conley, R., Tamminga, C., Pandey, G., 2001. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. *J. Neurochem.* 77, 916–928.
- Dwivedi, Y., Rao, J.S., Rizavi, H.S., Kotowski, J., Conley, R.R., Roberts, R.C., Tamminga, C.A., Pandey, G.N., 2003a. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. *Arch. Gen. Psychiatry* 60, 273–282.
- Dwivedi, Y., Rizavi, H.S., Conley, R.R., Roberts, R.C., Tamminga, C.A., Pandey, G.N., 2003b. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. *Arch. Gen. Psychiatry* 60, 804–815.
- Dwivedi, Y., Rizavi, H.S., Conley, R., Pandey, G.N., 2006. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. *Mol. Psychiatry* 11, 86–98.
- Dwivedi, Y., Rizavi, H.S., Teppen, T., Zhang, H., Mondal, A., Roberts, R.C., Conley, R.R., Pandey, G.N., 2008. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. *Neuropsychopharmacology* 33, 2324–2340.
- Dwivedi, Y., Rizavi, H.S., Zhang, H., Mondal, A.C., Roberts, R.C., Conley, R.R., Pandey, G.N., 2009a. Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide. *Biol. Psychiatry* 65, 319–328.
- Dwivedi, Y., Rizavi, H.S., Zhang, H., Roberts, R.C., Conley, R.R., Pandey, G.N., 2009b. Aberrant extracellular signal-regulated kinase (ERK) 1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). *Int. J. Neuropsychopharmacol.* 12, 1337–1354.
- Dwivedi, Y., Rizavi, H.S., Zhang, H., Roberts, R.C., Conley, R.R., Pandey, G.N., 2010. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. *Biol. Psychiatry* 67, 1017–1025.
- Fan, W., Yang, H., Sun, Y., Zhang, J., Li, G., Zheng, Y., Liu, Y., 2017. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. *Oncotarget* 8, 2356.
- Fazakas-DeHoog, L.L., Rnic, K., Dozois, D.J., 2017. A cognitive distortions and deficits model of suicide ideation. *Eur. J. Psychol.* 13, 178.
- Gilbert, A.M., Gamo, J.L., Braga, R.J., Shaya, Y., Goldberg, T.E., Malhotra, A.K., Burdick, K.E., 2011. Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? *J. Clin. Psychiatry* 72, 1027–1033.
- Glavan, D., Gheorman, V., Gresita, A., Hermann, D.M., Udristoiu, I., Popa-Wagner, A., 2021. Identification of transcriptome alterations in the prefrontal cortex, hippocampus, amygdala and hippocampus of suicide victims. *Sci. Rep.* 11, 1–15.
- González, A.M., Pascual, J., Meana, J.J., Barturen, F., Del Arco, C., Pazos, A., García-Sevilla, J.A., 1994. Autoradiographic demonstration of increased α -adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. *J. Neurochem.* 63, 256–265.
- Grunebaum, M.F., Ellis, S.P., Keilp, J.G., Moitra, V.K., Cooper, T.B., Marver, J.E., Burke, A.K., Milak, M.S., Sublette, M.E., Oquendo, M.A., 2017. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. *Bipolar Disord.* 19, 176–183.
- Grunebaum, M.F., Galfalvy, H.C., Choo, T.-H., Keilp, J.G., Moitra, V.K., Parris, M.S., Marver, J.E., Burke, A.K., Milak, M.S., Sublette, M.E., 2018. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. *Am. J. Psychiatry* 175, 327–335.
- Günak, M.M., Barnes, D.E., Yaffe, K., Li, Y., Byers, A.L., 2021. Risk of suicide attempt in patients with recent diagnosis of mild cognitive impairment or dementia. *JAMA Psychiatry*.
- Gurguis, G.N., Turkka, J., Laruelle, M., Kleinman, J., Linnoila, M., 1999. Coupling efficiency of brain β -adrenergic receptors to Gs protein in suicide, alcoholism and control subjects. *Psychopharmacology* 145, 31–38.
- Hamson, D.K., Wainwright, S.R., Taylor, J., Jones, B., Watson, N.V., Galea, L.A., 2013. Androgens increase survival of adult-born neurons in the dentate gyrus by an androgen receptor-dependent mechanism in male rats. *Endocrinology* 154, 3294–3304.
- Hanseeuw, B.J., Schultz, A.P., Betensky, R.A., Sperling, R.A., Johnson, K.A., 2016. Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. *Alzheimer's Dementia* 12, 1288–1296.
- Hetrick, S.E., Yuen, H.P., Bailey, E., Cox, G.R., Templer, K., Rice, S.M., Bendall, S., Robinson, J., 2017. Internet-based cognitive behavioural therapy for young people with suicide-related behaviour (Reframe-IT): a randomised controlled trial. *Evid. Ment. Health* 20, 76–82.
- Hoehne, A., Richard-Devantoy, S., Ding, Y., Turecki, G., Jollant, F., 2015. First-degree relatives of suicide completers may have impaired decision-making but functional cognitive control. *J. Psychiatr. Res.* 68, 192–197.
- Huber, R.S., Sheth, C., Renshaw, P.F., Yurgelun-Todd, D.A., McGlade, E.C., 2020. Suicide ideation and neurocognition among 9- and 10-year old children in the Adolescent Brain Cognitive Development (ABCD) study. *Arch. Suicide Res.* 1–15.
- Jabbi, M., Arasappan, D., Eickhoff, S.B., Strakowski, S.M., Nemeroff, C.B., Hofmann, H. A., 2020. Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. *J. Psychiatr. Res.* 127, 62–74.
- Jahn, D.R., Cukrowicz, K.C., Mitchell, S.M., Poindexter, E.K., Guidry, E.T., 2015. The mediating role of perceived burdensomeness in relations between domains of cognitive functioning and indicators of suicide risk. *J. Clin. Psychol.* 71, 908–919.
- Jankowski, M.S., Erdley, C.A., Schwartz-Mette, R.A., 2020. Social-cognitive risk for suicide and new relationship formation: False perception, self-fulfilling prophecy, or both? *Suicide Life. Behav.*
- Jiao, L., Duan, X., Cui, Q., Chen, H., Liao, W., 2019. More than just statics: temporal dynamics of intrinsic brain activity predicts the suicidal ideation in depressed patients. *Psychol. Med.* 49, 852–860.
- Johnston, J.A., Wang, F., Liu, J., Blond, B.N., Wallace, A., Liu, J., Spencer, L., Lippard, E. T.C., Purves, K.L., Landeros-Weisenberger, A., 2017. Multimodal neuroimaging of frontolimbic structure and function associated with suicide attempts in adolescents and young adults with bipolar disorder. *Am. J. Psychiatry*.
- Joyce, J.N., Lexow, N., Kim, S.J., Artyomshyn, R., Senzou, S., Lawrence, D., Cassanova, M.F., Kleinman, J.E., Bird, E.D., Winokur, A., 1992. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics. *Synapse* 10, 228–246.
- Kang, W., Shin, J.H., Han, K.M., Kim, A., Kang, Y., Kang, J., Tae, W.S., Paik, J.W., Lee, H. W., Seong, J.K., 2020. Local shape volume alterations in subcortical structures of suicide attempters with major depressive disorder. *Hum. Brain Mapp.* 41, 4925–4934.
- Kang, M.J., Kulcar, E., Chandrasena, R., Anjum, M.-R., Fairbairn, J., Hawken, E.R., Vazquez, G.H., 2021. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. *Psychiatry Res.* 296, 113645.
- Karege, F., Vaudan, G., Schwald, M., Perroud, N., La Harpe, R., 2005. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. *Mol. Brain Res.* 136, 29–37.
- Khoury, J., Pechtel, P., Andersen, C., Teicher, M., Lyons-Ruth, K., 2019. Relations among maternal withdrawal in infancy, borderline features, suicidality/self-injury, and adult hippocampal volume: a 30-year longitudinal study. *Behav. Brain Res.* 374, 112139.
- Klok, M.D., Alt, S.R., Lafitte, A.J.I., Turner, J.D., Lakke, E.A., Huitinga, I., Muller, C.P., Zitman, F.G., De Kloet, E.R., DeRijk, R.H., 2011. Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. *J. Psychiatr. Res.* 45, 871–878.

- Kobayashi, K., Shimizu, E., Hashimoto, K., Mitsumori, M., Koike, K., Okamura, N., Koizumi, H., Ohgake, S., Matsuzawa, D., Zhang, L., 2005. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 29, 658–663.
- Kokkinou, M., Ashok, A.H., Howes, O.D., 2018. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. *Mol. Psychiatry* 23, 59–69.
- Kokkinou, M., Irvine, E.E., Bonsall, D.R., Natesan, S., Wells, L.A., Smith, M., Glegola, J., Paul, E.J., Tossell, K., Veronese, M., 2020. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. *Mol. Psychiatry* 1–15.
- Kouter, K., Zupanc, T., Paska, A.V., 2019. Genome-wide DNA methylation in suicide victims revealing impact on gene expression. *J. Affect. Disord.* 253, 419–425.
- Labonté, B., Yerko, V., Gross, J., Mechawar, N., Meaney, M.J., Szyf, M., Turecki, G., 2012. Differential glucocorticoid receptor exon 1B, 1C, and 1H expression and methylation in suicide completers with a history of childhood abuse. *Biol. Psychiatry* 72, 41–48.
- Labonté, B., Suderman, M., Maussion, G., Lopez, J.P., Navarro-Sánchez, L., Yerko, V., Mechawar, N., Szyf, M., Meaney, M.J., Turecki, G., 2013. Genome-wide methylation changes in the brains of suicide completers. *Am. J. Psychiatry* 170, 511–520.
- Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F.J., Sanacora, G., 2012. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. *Biol. Psychiatry* 72, e27.
- Lake, B.B., Codeluppi, S., Yung, Y.C., Gao, D., Chun, J., Kharchenko, P.V., Linnarsson, S., Zhang, K., 2017. A comparative strategy for single-nucleus and single-cell transcriptomes confirms accuracy in predicted cell-type expression from nuclear RNA. *Sci. Rep.* 7, 1–8.
- Lan, M.J., Rizk, M.M., Pantazatos, S.P., Rubin-Falcone, H., Miller, J.M., Sublette, M.E., Oquendo, M.A., Keilp, J.G., Mann, J.J., 2019. Resting-state amplitude of low-frequency fluctuation is associated with suicidal ideation. *Depress. Anxiety* 36, 433–441.
- Laugesen, K., Farkas, D.K., Vestergaard, M., Jørgensen, J.O.L., Petersen, I., Sørensen, H. T., 2021. Glucocorticoid use and risk of suicide: a Danish population-based case-control study. *World Psychiatry* 20, 142.
- Lavigne, J.E., Hür, K., Kane, C., Au, A., Bishop, T.M., Pigeon, W.R., 2019. Prescription medications for the treatment of insomnia and risk of suicide attempt: a comparative safety study. *J. Gen. Intern. Med.* 34, 1554–1563.
- Lee, Y., Syeda, K., Maruschak, N.A., Cha, D.S., Mansur, R.B., Wium-Andersen, I.K., Woldeyohannes, H.O., Rosenblatt, J.D., McIntyre, R.S., 2016. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. *J. Clin. Psychopharmacol.* 36, 50–56.
- Leng, K., Li, E., Eser, R., Piergies, A., Sit, R., Tan, M., Neff, N., Li, S.H., Rodriguez, R.D., Suemoto, C.K., 2021. Molecular characterization of selectively vulnerable neurons in Alzheimer's disease. *Nat. Neurosci.* 24, 276–287.
- Lin, T.-J., Ko, H.-C., Wu, J.Y.-W., Oei, T.P., Lane, H.-Y., Chen, C.-H., 2019. The effectiveness of dialectical behavior therapy skills training group vs. cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. *Arch. Suicide Res.* 23, 82–99.
- Little, K.Y., McLaughlin, D.P., Ranc, J., Gilmore, J.F., Watson, S.J., Carroll, F.I., Butts, J.D., 1997. Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide. *Biol. Psychiatry* 41, 1156–1164.
- Liu, R.-J., Lee, F.S., Li, X.-Y., Bambico, F., Duman, R.S., Aghajanian, G.K., 2012. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. *Biol. Psychiatry* 71, 996–1005.
- Longo, S.K., Guo, M.G., Ji, A.L., Khavari, P.A., 2021. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. *Nat. Rev. Genet.* 1–18.
- López, J.F., Chalmers, D.T., Little, K.Y., Watson, S.J., 1998. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. *Biol. Psychiatry* 43, 547–573.
- Lowther, S., De Paermentier, F., Cheetham, S.C., Crompton, M.R., Katona, C.L., Horton, R.W., 1997. 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. *J. Affect. Disord.* 42, 199–207.
- Lucassen, P.J., Stumpel, M.W., Wang, Q., Aronica, E., 2010. Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. *Neuropharmacology* 58, 940–949.
- Lucassen, P.J., Fitzsimons, C., Korosi, A., Joels, M., Belzung, C., Abrous, D., 2013. Stressing new neurons into depression? *Mol. Psychiatry* 18, 396.
- Lucassen, P.J., Oomen, C.A., Naninck, E.F., Fitzsimons, C.P., van Dam, A.-M., Czech, B., Korosi, A., 2015. Regulation of adult neurogenesis and plasticity by (early) stress, glucocorticoids, and inflammation. *Cold Spring Harb. Perspect. Biol.* 7, a021303.
- Luo, Y., Yu, Y., Zhang, M., He, H., Fan, N., 2020. Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling. *Mol. Psychiatry* 1–17.
- Lutz, P., Mechawar, N., Turecki, G., 2017. Neuropathology of suicide: recent findings and future directions. *Mol. Psychiatry* 22, 1395–1412.
- Mahar, I., Labonté, B., Yogendran, S., Isingrini, E., Perret, L., Davoli, M., Rachalski, A., Giros, B., Turecki, G., Mechawar, N., 2017. Disrupted hippocampal neuregulin-1/ ErbB3 signaling and dentate gyrus granule cell alterations in suicide. *Transl. Psychiatry* 7, e1161.
- Marlatt, M.W., Potter, M.C., Lucassen, P.J., van Praag, H., 2012. Running throughout middle-age improves memory function, hippocampal neurogenesis, and BDNF levels in female C57BL/6J mice. *Dev. Neurobiol.* 72, 943–952.
- Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J.Z., Menon, M., He, L., Abdurrob, F., Jiang, X., 2019. Author correction: single-cell transcriptomic analysis of Alzheimer's disease. *Nature* 571, E1.
- McGirr, A., Dombrovski, A.Y., Butters, M.A., Clark, L., Szanto, K., 2012. Deterministic learning and attempted suicide among older depressed individuals: cognitive assessment using the Wisconsin Card Sorting Task. *J. Psychiatr. Res.* 46, 226–232.
- McGowan, P.O., Sasaki, A., Huang, T.C., Unterberger, A., Suderman, M., Ernst, C., Meaney, M.J., Turecki, G., Szyf, M., 2008. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. *PLoS One* 3, e2085.
- McGowan, P.O., Sasaki, A., D'alesio, A.C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., Meaney, M.J., 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat. Neurosci.* 12, 342–348.
- Meana, J.J., Barturen, F., Garcia-Sevilla, J.A., 1992. α 2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. *Biol. Psychiatry* 31, 471–490.
- Medina, A., Seasholtz, A.F., Sharma, V., Burke, S., Bunney Jr, W., Myers, R.M., Schatzberg, A., Akil, H., Watson, S.J., 2013. Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. *J. Psychiatr. Res.* 47, 307–314.
- Miranda, R., Gallagher, M., Bauchner, B., Vaysman, R., Marroquín, B., 2012. Cognitive inflexibility as a prospective predictor of suicidal ideation among young adults with a suicide attempt history. *Depress. Anxiety* 29, 180–186.
- Miszta, P., Pańcyszyn-Trzewik, P., Nowak, G., Sowa-Kućma, M., 2020. Epigenetic marks and their relationship with BDNF in the brain of suicide victims. *PLoS One* 15, e0239335.
- Molendijk, M., Spinhoven, P., Polak, M., Bus, B., Penninx, B., Elzinga, B., 2014. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). *Mol. Psychiatry* 19, 791–800.
- Mollan, K.R., Smurzynski, M., Eron, J.J., Daar, E.S., Campbell, T.B., Sax, P.E., Gulick, R.M., Na, L., O'Keefe, L., Robertson, K.R., 2014. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann. Intern. Med.* 161, 1–10.
- Mollan, K.R., Tierney, C., Hellwege, J.N., Eron, J.J., Hudgens, M.G., Gulick, R.M., Haubrich, R., Sax, P.E., Campbell, T.B., Daar, E.S., 2017. Race/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants. *J. Infect. Dis.* 216, 554–564.
- Moniz, M., de Jesus, S.N., Pacheco, A., Gonçalves, E., Viseu, J., Brás, M., Silva, D., Batista, S., 2017. The influence of planning and response inhibition on cognitive functioning of non-psychotic unipolar depressed suicide attempters. *Eur. J. Psychol.* 13, 717.
- Morley, K.C., Sitharhan, G., Haber, P.S., Tucker, P., Sitharhan, T., 2014. The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: a multisite randomized controlled trial. *J. Consult. Clin. Psychol.* 82, 130.
- Müller, M.B., Lucassen, P.J., Yassouridis, A., Hoogendijk, W.J., Holsboer, F., Swaab, D.F., 2001. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. *Eur. J. Neurosci.* 14, 1603–1612.
- Nagy, C., Maitra, M., Tanti, A., Suderman, M., Thérout, J.-F., Davoli, M.A., Perlman, K., Yerko, V., Wang, Y.C., Tripathy, S.J., 2020. Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. *Nat. Neurosci.* 23, 771–781.
- Nelson, M.D., Saykin, A.J., Flashman, L.A., Riordan, H.J., 1998. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. *Arch. Gen. Psychiatry* 55, 433–440.
- Nevin, R.L., 2012. Mefloquine blockade of connexin 36 and connexin 43 gap junctions and risk of suicide. *Biol. Psychiatry* 71, e1–e2.
- Nichols, D.E., Grob, C.S., 2018. Is LSD toxic? *Forensic Sci. Int.* 284, 141–145.
- Niu, J., Tsai, H.-H., Hoi, K.K., Huang, N., Yu, G., Kim, K., Baranzini, S.E., Xiao, L., Chan, J.R., Fancy, S.P., 2019. Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering CNS inflammation. *Nat. Neurosci.* 22, 709–718.
- Notaras, M., van den Buuse, M., 2020. Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. *Mol. Psychiatry* 25, 2251–2274.
- Notaras, M., Hill, R., Gogos, J., van den Buuse, M., 2016. BDNF Val66Met genotype determines hippocampus-dependent behavior via sensitivity to glucocorticoid signaling. *Mol. Psychiatry* 21, 730–732.
- Nowak, W., Grendas, L.N., Sanmarco, L.M., Estecho, I.G., Arena, Á.R., Eberhardt, N., Rodante, D.E., Aoki, M.P., Daray, F.M., Silva, E.A.C., 2019. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. *EBioMedicine* 50, 290–305.
- Nugent, A.C., Ballard, E.D., Gilbert, J.R., Tewarie, P.K., Brookes, M.J., Zarate Jr, C.A., 2020. Multilayer MEG functional connectivity as a potential marker for suicidal thoughts in major depressive disorder. *Neuroimage Clin.* 28, 102378.
- Oglesby, M.E., Capron, D.W., Raines, A.M., Schmidt, N.B., 2015. Anxiety sensitivity cognitive concerns predict suicide risk. *Schizophr. Res.* 226, 252–256.
- Olah, M., Menon, V., Habib, N., Taga, M.F., Ma, Y., Yung, C.J., Cimpean, M., Khairallah, A., Coronas-Samano, G., Sankowski, R., 2020. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease. *Nat. Commun.* 11, 1–18.
- Olsson, P., Wiktorsson, S., Sacuiu, S., Marlow, T., Östling, S., Fässberg, M.M., Skoog, I., Waern, M., 2016. Cognitive function in older suicide attempters and a population-based comparison group. *J. Geriatr. Psychiatry Neurol.* 29, 133–141.

- Ophinni, Y., Siste, K., Wiwie, M., Anindyajati, G., Hanafi, E., Damayanti, R., Hayashi, Y., 2020. Suicidal ideation, psychopathology and associated factors among HIV-infected adults in Indonesia. *BMC Psychiatry* 20, 1–10.
- Owen, F., Chambers, D., Cooper, S., Crow, T., Johnson, J., Lofthouse, R., Poulter, M., 1986. Serotonergic mechanisms in brains of suicide victims. *Brain Res.* 362, 185–188.
- Paine, M.R., Ellis, S.R., Maloney, D., Heeren, R.M., Verhaert, P.D., 2018. Digestion-free analysis of peptides from 30-year-old formalin-fixed, paraffin-embedded tissue by mass spectrometry imaging. *Anal. Chem.* 90, 9272–9280.
- Pandey, G.N., Dwivedi, Y., Rizavi, H.S., Ren, X., Pandey, S.C., Pesold, C., Roberts, R.C., Conley, R.R., Tamminga, C.A., 2002. Higher expression of serotonin 5-HT_{2A} receptors in the postmortem brains of teenage suicide victims. *Am. J. Psychiatry* 159, 419–429.
- Pandey, G.N., Dwivedi, Y., Ren, X., Rizavi, H.S., Roberts, R.C., Conley, R.R., Tamminga, C., 2003. Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. *J. Psychiatr. Res.* 37, 421–432.
- Pandey, G.N., Dwivedi, Y., Ren, X., Rizavi, H.S., Faludi, G., Sarosi, A., Palkovits, M., 2006. Regional distribution and relative abundance of serotonin 2C receptors in human brain: effect of suicide. *Neurochem. Res.* 31, 167–176.
- Pandey, G.N., Ren, X., Rizavi, H.S., Conley, R.R., Roberts, R.C., Dwivedi, Y., 2008. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. *Int. J. Neuropsychopharmacol.* 11, 1047–1061.
- Pandey, G.N., Dwivedi, Y., Rizavi, H.S., Teppen, T., Gaszner, G.L., Roberts, R.C., Conley, R.R., 2009. GSK-3 β gene expression in human postmortem brain: regional distribution, effects of age and suicide. *Neurochem. Res.* 34, 274–285.
- Pandey, G.N., Rizavi, H.S., Ren, X., Dwivedi, Y., Palkovits, M., 2013. Region-specific alterations in glucocorticoid receptor expression in the postmortem brain of teenage suicide victims. *Psychoneuroendocrinology* 38, 2628–2639.
- Pandey, G.N., Rizavi, H.S., Bhaumik, R., Ren, X., 2019. Increased protein and mRNA expression of corticotropin-releasing factor (CRF), decreased CRF receptors and CRF binding protein in specific postmortem brain areas of teenage suicide subjects. *Psychoneuroendocrinology* 106, 233–243.
- Pantazatos, S.P., Huang, Y., Rosoklija, G.B., Dwork, A.J., Arango, V., Mann, J.J., 2017. Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. *Mol. Psychiatry* 22, 760–773.
- Peters, R.B., Xavier, J., Mondin, T.C., Cardoso, Td.A., Ferreira, F.B., Teixeira, L., Gräeff, K., Quevedo, Ld.A., Jansen, K., Souza, L.D., 2020. BDNF Val66Met polymorphism and resilience in major depressive disorder: the impact of cognitive psychotherapy. *Braz. J. Psychiatry* 43, 22–28.
- Pompili, M., Lester, D., Girardi, P., Tatarelli, R., 2007. High suicide risk after the development of cognitive and working memory deficits caused by cannabis, cocaine and ecstasy use. *Subst. Abuse.* 28, 25–30.
- Punzi, G., Ursini, G., Viscanti, G., Radulescu, E., Shin, J.H., Quarto, T., Citanesi, R., Blasi, G., Jaffe, A.E., Deep-Soboslay, A., 2019. Association of a noncoding RNA postmortem with suicide by violent means and in vivo with aggressive phenotypes. *Biol. Psychiatry* 85, 417–424.
- Qin, P., Agerbo, E., Mortensen, P.B., 2002. Suicide risk in relation to family history of completed suicide and psychiatric disorders: a nested case-control study based on longitudinal registers. *Lancet* 360, 1126–1130.
- Ren, X., Rizavi, H.S., Khan, M.A., Dwivedi, Y., Pandey, G.N., 2013. Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3 β and β -catenin. *Int. J. Neuropsychopharmacol.* 16, 945–955.
- Reutfors, J., Bahmanyar, S., Jönsson, E.G., Brandt, L., Bodén, R., Ekblom, A., Ösby, U., 2013. Medication and suicide risk in schizophrenia: a nested case-control study. *Schizophr. Res.* 150, 416–420.
- Ritchie, E.C., Block, J., Nevin, R.L., 2013. Psychiatric side effects of mefloquine: applications to forensic psychiatry. *J. Am. Acad. Psychiatry Law Online* 41, 224–235.
- Roberge, E.M., Bryan, C.J., Peterson, A., Rudd, M.D., 2019. Variables associated with reductions in insomnia severity among acutely suicidal patients receiving brief cognitive behavioral therapy for suicide prevention. *J. Affect. Disord.* 252, 230–236.
- Rosel, P., Arranz, B., Vallejo, J., Oros, M., Menchon, J., Alvarez, P., Navarro, M., 1997. High affinity [3H] imipramine and [3H] paroxetine binding sites in suicide brains. *J. Neural Transm.* 104, 921–929.
- Rosel, P., Arranz, B., Vallejo, J., Oros, M., Crespo, J.M., Menchon, J.M., Navarro, M.A., 1998. Variations in [3H] imipramine and 5-HT_{2A} but not [3H] paroxetine binding sites in suicide brains. *Psychiatry Res. Neuroimaging* 82, 161–170.
- Rosel, P., Arranz, B., San, L., Vallejo, J., Crespo, J.M., Urretavizcaya, M., Navarro, M.A., 2000. Altered 5-HT_{2A} binding sites and second messenger inositol trisphosphate (IP₃) levels in hippocampus but not in frontal cortex from depressed suicide victims. *Psychiatry Res. Neuroimaging* 99, 173–181.
- Rosel, P., Arranz, B., Urretavizcaya, M., Oros, M., San, L., Navarro, M.A., 2004. Altered 5-HT_{2A} and 5-HT₄ postsynaptic receptors and their intracellular signalling systems IP₃ and cAMP in brains from depressed violent suicide victims. *Neuropsychobiology* 49, 189–195.
- Roth, B., Hamblin, M., Ciaranello, R., 1990. Regulation of 5-HT₂ and 5-HT_{1C} serotonin receptor levels. Methodology and mechanisms. *Neuropsychopharmacology* 3, 427–433.
- Roush, J.F., Brown, S.L., Mitchell, S.M., Cukrowicz, K.C., 2019. Experiential avoidance, cognitive fusion, and suicide ideation among psychiatric inpatients: the role of thwarted interpersonal needs. *Psychother. Res.* 29, 514–523.
- Sarkinaite, M., Gleizniene, R., Adomaitiene, V., Dambrauskienė, K., Raskauskiene, N., Steibliene, V., 2021. Volumetric MRI analysis of brain structures in patients with history of first and repeated suicide attempts: a cross sectional study. *Diagnostics* 11, 488.
- Schenkel, L.C., Segal, J., Becker, J.A., Manfro, G.G., Bianchin, M.M., Leistner-Segal, S., 2010. The BDNF Val66Met polymorphism is an independent risk factor for high lethality in suicide attempts of depressed patients. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 34, 940–944.
- Sequeira, A., Mamdani, F., Ernst, C., Vawter, M.P., Bunney, W.E., Lebel, V., Rehal, S., Klempan, T., Gratton, A., Benkelfat, C., 2009. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. *PLoS One* 4, e6585.
- Shariatorji, M., Nilsson, A., Fridjonsdottir, E., Vallianatou, T., Källback, P., Katan, L., Sävmarker, J., Mantas, I., Zhang, X., Bezar, E., 2019. Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging. *Nat. Methods* 16, 1021–1028.
- Sher, L., Grunebaum, M.F., Sullivan, G.M., Burke, A.K., Cooper, T.B., Mann, J.J., Oquendo, M.A., 2012. Testosterone levels in suicide attempters with bipolar disorder. *J. Psychiatr. Res.* 46, 1267–1271.
- Shirayama, Y., Chen, A.C.-H., Nakagawa, S., Russell, D.S., Duman, R.S., 2002. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. *J. Neurosci.* 22, 3251–3261.
- Sinyor, M., Williams, M., Mitchell, R., Zaheer, R., Bryan, C.J., Schaffer, A., Westreich, N., Ellis, J., Goldstein, B.I., Cheung, A.H., 2020. Cognitive behavioral therapy for suicide prevention in youth admitted to hospital following an episode of self-harm: a pilot randomized controlled trial. *J. Affect. Disord.* 266, 686–694.
- Snyder, J.S., Soumier, A., Brewer, M., Pickel, J., Cameron, H.A., 2011. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. *Nature* 476, 458–461.
- Soloff, P.H., Price, J.C., Meltzer, C.C., Fabio, A., Frank, G.K., Kaye, W.H., 2007. 5HT_{2A} receptor binding is increased in borderline personality disorder. *Biol. Psychiatry* 62, 580–587.
- Sowa-Kućma, M., Szweczyk, B., Sadiłk, K., Piekoszewski, W., Trela, F., Opoka, W., Poleszak, E., Pilc, A., Nowak, G., 2013. Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. *J. Affect. Disord.* 151, 924–931.
- Spoletini, I., Piras, F., Fagioli, S., Rubino, I.A., Martinotti, G., Siracusano, A., Caltagirone, C., Spalletta, G., 2011. Suicidal attempts and increased right amygdala volume in schizophrenia. *Schizophr. Res.* 125, 30–40.
- Stewart, J.G., Glenn, C.R., Esposito, E.C., Cha, C.B., Nock, M.K., Auerbach, R.P., 2017. Cognitive control deficits differentiate adolescent suicide ideators from attempters. *J. Clin. Psychiatry* 78, 614–621.
- Strack, R., 2021. Accelerating imaging transcriptomics. *Nat. Methods* 18, 594.
- Surget, A., Tanti, A., Leonardo, E., Laugeray, A., Rainer, Q., Touma, C., Palme, R., Griebel, G., Iburguen-Vargas, Y., Hen, R., 2011. Antidepressants recruit new neurons to improve stress response regulation. *Mol. Psychiatry* 16, 1177–1188.
- Suzuki, J., Poklis, J.L., Poklis, A., 2014. “My friend said it was good LSD”: a suicide attempt following analytically confirmed 25I-NBOMe ingestion. *J. Psychoactive Drugs* 46, 379–382.
- Tang, W., Shin, J.D., Jadhav, S.P., 2021. Multiple time-scales of decision-making in the hippocampus and prefrontal cortex. *Elife* 10, e66227.
- Teicher, M.H., Anderson, C.M., Polcari, A., 2012. Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus, and subiculum. *Proc. Natl. Acad. Sci.* 109, E563–E572.
- Thrupp, N., Frigerio, C.S., Wolfs, L., Skene, N.G., Fattorelli, N., Poovathingal, S., Fournie, Y., Matthews, P.M., Theys, T., Mancuso, R., 2020. Single-nucleus RNA-Seq is not suitable for detection of microglial activation genes in humans. *Cell Rep.* 32, 108189.
- Tubbs, A.S., Fernandez, F.-X., Ghani, S.B., Karp, J.F., Patel, S.I., Parthasarathy, S., Grandner, M.A., 2021. Prescription medications for insomnia are associated with suicidal thoughts and behaviors in two nationally representative samples. *J. Clin. Sleep Med.* 9096.
- Tucker, R.P., Lengel, G.J., Smith, C.E., Capron, D.W., Mullins-Sweatt, S.N., Wingate, L.R., 2016. Maladaptive five factor model personality traits associated with borderline personality disorder indirectly affect susceptibility to suicide ideation through increased anxiety sensitivity cognitive concerns. *Psychiatry Res.* 246, 432–437.
- Turecki, G., Brent, D.A., Gunnell, D., O’Connor, R.C., Oquendo, M.A., Pirkis, J., Stanley, B.H., 2019. Suicide and suicide risk. *Nat. Rev. Dis. Primers* 5, 1–22.
- Vaquero-Lorenzo, C., Baca-Garcia, E., Diaz-Hernandez, M., Perez-Rodriguez, M.M., Fernandez-Navarro, P., Giner, L., Carballo, J.J., Saiz-Ruiz, J., Fernandez-Piqueras, J., Baldomero, E.B., 2008. Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 147, 645–649.
- Vawter, M., Thatcher, L., Usen, N., Hyde, T., Kleinman, J., Freed, W., 2002. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. *Mol. Psychiatry* 7, 571–578.
- Voleti, B., Duman, R., 2012. The roles of neurotrophic factor and Wnt signaling in depression. *Clin. Pharmacol. Ther.* 91, 333–338.
- Wagner, G., Li, M., Sacchet, M.D., Richard-Devantoy, S., Turecki, G., Bär, K.-J., Gotlib, I. H., Walter, M., Jollant, F., 2021. Functional network alterations differently associated with suicidal ideas and acts in depressed patients: an indirect support to the transition model. *Transl. Psychiatry* 11, 1–11.
- Wang, Q., Joels, M., Swaab, D., Lucassen, P., 2012. Hippocampal GR expression is increased in elderly depressed females. *Neuropharmacology* 62, 527–533.
- Wang, Q., Van Heerikhuizen, J., Aronica, E., Kawata, M., Seress, L., Joels, M., Swaab, D.F., Lucassen, P.J., 2013. Glucocorticoid receptor protein expression in human hippocampus; stability with age. *Neurobiol. Aging* 34, 1662–1673.
- Wang, L., Zhao, Y., Edmiston, E.K., Womer, F.Y., Zhang, R., Zhao, P., Jiang, X., Wu, F., Kong, L., Zhou, Y., Tang, Y., Wei, S., 2019. Structural and functional abnormalities of

- amygdala and prefrontal cortex in major depressive disorder with suicide attempts. *Front. Psychiatry* 10, 923.
- Weinstein, S.M., Cruz, R.A., Isaia, A.R., Peters, A.T., West, A.E., 2018. Child-and family-focused cognitive behavioral therapy for pediatric bipolar disorder: applications for suicide prevention. *Suicide Life. Behav.* 48, 797–811.
- Weiser, M., Fenchel, D., Werbeloff, N., Goldberg, S., Fruchter, E., Reichenberg, A., Burshtein, S., Large, M., Davidson, M., Lubin, G., 2017. The association between premorbid cognitive ability and social functioning and suicide among young men: a historical-prospective cohort study. *Eur. Neuropsychopharmacol.* 27, 1–7.
- Weng, J.-C., Chou, Y.-S., Tsai, Y.-H., Lee, C.-T., Hsieh, M.-H., Chen, V.C.-H., 2019. Connectome analysis of brain functional network alterations in depressive patients with suicidal attempt. *J. Clin. Med.* 8, 1966.
- WHO, 2021. Suicide.
- Williams, N.R., Heifets, B.D., Bentzley, B.S., Blasey, C., Sudheimer, K.D., Hawkins, J., Lyons, D.M., Schatzberg, A.F., 2019. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. *Mol. Psychiatry* 24, 1779–1786.
- Wixted, J.T., Squire, L.R., Jang, Y., Papesh, M.H., Goldinger, S.D., Kuhn, J.R., Smith, K. A., Treiman, D.M., Steinmetz, P.N., 2014. Sparse and distributed coding of episodic memory in neurons of the human hippocampus. *Proc. Natl. Acad. Sci.* 111, 9621–9626.
- Yohn, C.N., Gergues, M.M., Samuels, B.A., 2017. The role of 5-HT receptors in depression. *Mol. Brain* 10, 1–12.
- Youssef, M., Atsak, P., Cardenas, J., Kosmidis, S., Leonardo, E.D., Dranovsky, A., 2019. Early life stress delays hippocampal development and diminishes the adult stem cell pool in mice. *Sci. Rep.* 9, 1–10.
- Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., 2016. Suicide prevention strategies revisited: 10-year systematic review. *Lancet Psychiatry* 3, 646–659.
- Zanos, P., Gould, T.D., 2018. Mechanisms of ketamine action as an antidepressant. *Mol. Psychiatry* 23, 801–811.
- Zhan, Y., Zhang, B., Zhou, Y., Zheng, W., Liu, W., Wang, C., Li, H., Chen, L., Yu, L., Walter, M., 2019. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. *J. Affect. Disord.* 251, 205–212.
- Zhang, J.-M., Tonelli, L., Regenold, W.T., McCarthy, M.M., 2010. Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats. *Neuroscience* 169, 544–554.
- Zhang, L., Verwer, R.W., Lucassen, P.J., Huitinga, I., Swaab, D.F., 2020a. Prefrontal cortex alterations in glia gene expression in schizophrenia with and without suicide. *J. Psychiatr. Res.* 121, 31–38.
- Zhang, L., Verwer, R.W., Lucassen, P.J., Huitinga, I., Swaab, D.F., 2020b. Sex difference in glia gene expression in the dorsolateral prefrontal cortex in bipolar disorder: relation to psychotic features. *J. Psychiatr. Res.* 125, 66–74.
- Zhang, L., Verwer, R.W., Zhao, J., Huitinga, I., Lucassen, P.J., Swaab, D.F., 2021a. Changes in glial gene expression in the prefrontal cortex in relation to major depressive disorder, suicide and psychotic features. *J. Affect. Disord.* 295, 893–903.
- Zhang, Q., Hong, S., Cao, J., Zhou, Y., Xu, X., Ai, M., Kuang, L., 2021b. Hippocampal subfield volumes in major depressive disorder adolescents with a history of suicide attempt. *Biomed Res. Int.* 2021.
- Zhao, J., Lucassen, P.J., Swaab, D.F., 2019. Suicide is a confounder in postmortem studies on depression. *Biol. Psychiatry* 86, e37–e40.
- Zhou, Y., Lutz, P.-E., Wang, Y.C., Ragoussis, J., Turecki, G., 2018. Global long non-coding RNA expression in the rostral anterior cingulate cortex of depressed suicides. *Transl. Psychiatry* 8, 1–13.